electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06 2023 - 8:00AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine and wellness company, today
announced the receipt of a license to import, distribute and market
gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) in
Indonesia. This follows the equivalent license approvals received
in Malaysia in September 2022 and in South Africa in March 2023.
“Gaining wider global approvals and opening supply routes for
gammaCore further validates the clinical evidence portfolio we have
behind our technology, and more importantly, broadens the
geographical access for patients and clinicians,” said Iain
Strickland, SVP, Global Sales and Strategy at electroCore. “The
product registration in Indonesia, South Africa and Malaysia
represent the first registrations we have in both the Far East and
the African continent.”
Mr. Strickland continued, “It’s an exciting time to be building
new clinician networks and we look forward to supporting our
distributors Kromax South Asia and Byond Healthcare as they launch
in their respective territories. These regions have a combined
population of 367 million and represent a significant market
opportunity supported by local key opinion leaders, to whom we are
grateful for their ongoing support and desire to include gammaCore
nVNS, in their treatment considerations for headache patients.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving outcomes through its non-invasive vagus
nerve stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About gammaCore™gammaCore™ (nVNS) is the first
non-invasive, hand-held medical therapy applied at the neck to
treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore™ is intended to provide non-invasive vagus nerve
stimulation (nVNS) on the side of the neck for preventive treatment
of migraine and the acute treatment of pain associated with
migraine in patients 12 and older. gammaCore is also indicated for
adjunctive use for preventive treatment of cluster headache, acute
treatment of episodic cluster headache, and treatment of hemicrania
continua and paroxysmal hemicrania in adult patients. gammaCore
should not be used by people with an active implantable medical
device. Please refer to gammaCore.com or the Instructions for Use
for complete safety information, including indications,
contraindications, warnings, cautions, and instructions.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans as a potential alternative to opioids for
pain management; its pipeline or potential markets for its
technologies including treatment as a non-pharmaceutical
therapeutic option for a variety of pain conditions; the timing,
outcome and impact of regulatory, clinical and commercial
developments; the Company’s business prospects in Indonesia,
Malaysia and South Africa, and other new markets and other
statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to
pursue electroCore’s business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, the ability to commercialize gammaCore™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024